Adaptimmune Therapeutics PLC Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Adaptimmune Therapeutics PLC |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Adaptimmune's Q1 2025 10-Q is in, showing financial snapshots from March 31, 2025.
AI Summary
Adaptimmune Therapeutics PLC filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial position and operational updates. Key financial data points such as retained earnings, additional paid-in capital, and accumulated other comprehensive income for both March 31, 2025, and December 31, 2024, are presented.
Why It Matters
This filing provides investors with a quarterly update on Adaptimmune's financial health and performance, crucial for understanding the company's trajectory in the biopharmaceutical sector.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Adaptimmune Therapeutics PLC faces inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the fiscal quarter for this filing.)
- 20250513 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Adaptimmune Therapeutics PLC (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of the reporting period
- December 31, 2024 (date) — Previous reporting period end
FAQ
What are the key financial figures reported for Adaptimmune Therapeutics PLC as of March 31, 2025?
The filing includes data for us-gaap:RetainedEarningsMember, us-gaap:AdditionalPaidInCapitalMember, us-gaap:AccumulatedTranslationAdjustmentMember, us-gaap:AccumulatedOtherComprehensiveIncomeMember, and us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember as of March 31, 2025.
How do the financial figures as of March 31, 2025, compare to those from December 31, 2024?
The 10-Q provides comparative data for the same financial line items (retained earnings, additional paid-in capital, etc.) for both March 31, 2025, and December 31, 2024, allowing for period-over-period analysis.
What is the primary business of Adaptimmune Therapeutics PLC?
Adaptimmune Therapeutics PLC operates in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, SIC code 2836.
When was Adaptimmune Therapeutics PLC formerly known as Adaptimmune Ltd?
The company's name changed from Adaptimmune Ltd to Adaptimmune Therapeutics PLC on October 1, 2014.
What is the fiscal year end for Adaptimmune Therapeutics PLC?
Adaptimmune Therapeutics PLC's fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Adaptimmune Therapeutics PLC.